Top

Category: Cell and Gene Therapy


Cell and Gene Therapy, Clinical Trials, Industry, Research and Development

Pfizer, Sangamo resume haemophilia gene therapy trial

September 26, 2022

Via: Pharmaphorum

The phase 3 AFFINE trial was paused voluntarily by the two partners almost a year ago, and subsequently placed on hold by the FDA, after patients treated with the therapy produced higher than expected levels of Factor VIII – the […]


Cell and Gene Therapy, Clinical Trials, Industry, Research and Development

Pfizer, Sangamo set to resume gene therapy study after safety delay

September 23, 2022

Via: Biopharma Dive

Pfizer and Sangamo Therapeutics will soon resume a Phase 3 trial of their gene therapy for the blood disorder hemophilia A, nearly a year after safety concerns forced its suspension. Specifically, the companies said Thursday evening they plan to resume […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

GenScript and Avectas Partner on Next-Generation Cell Therapies

September 22, 2022

Via: GEN

GenScript and Avectas agreed to partner to develop an improved non-viral cell therapy manufacturing process. By combining Avectas’ cell engineering technology with GenScript’s expertise in synthetic long oligo production, the partnership aims to demonstrate a novel and efficient solution for […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

GenScript and Avectas link up to improve non-viral cell therapy processes

September 20, 2022

Via: Pharma Times

GenScript – the life-sciences research tools and services provider – and Avectas, a cell engineering technology company, are partnering to develop an improved non-viral cell therapy manufacturing process. The two companies are focusing on new methods for developing cell therapies […]


Cell and Gene Therapy, Industry

Back-to-back gene therapy approvals give Bluebird shot at survival

September 19, 2022

Via: Biopharma Dive

Until this August, just two gene therapies for inherited diseases were available in the U.S. Now, in the span of one month, that count has doubled, with the Food and Drug Administration approving new treatments for a rare blood condition […]


Cell and Gene Therapy, Industry

SparingVision raises €75m for eye disease gene therapies

September 14, 2022

Via: Pharmaphorum

The French biotech said the cash injection – which follows a €45 million Series A in 2020 – will also help it bring forward the first development candidate in a collaboration signed with gene-editing specialist Intellia Therapeutics last year, currently […]


Cell and Gene Therapy, Industry

Ori Biotech Partners with the Cell Therapy Manufacturing Center to Accelerate Cell Therapy Delivery

September 13, 2022

Via: Contract Pharma

Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technologies, and the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience Inc. and MD Anderson Cancer Center, have entered a collaborative partnership to develop industrial manufacturing […]


Cell and Gene Therapy, Industry

Potential Gene Therapy Developed for Childhood Blinding Disease

September 9, 2022

Via: GEN

Researchers at the National Eye Institute (NEI), part of the National Institutes of Health, have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that causes blindness […]


Cell and Gene Therapy, Industry

Stem cell-gene therapy shows promise in ALS safety trial

September 5, 2022

Via: World Pharma News

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This combined stem cell and gene therapy can potentially protect diseased motor neurons in the spinal cord of […]


Cell and Gene Therapy, Industry

Sangamo presses ahead with Fabry disease gene therapy

September 1, 2022

Via: Biopharma Dive

Sangamo Therapeutics is continuing to enroll and treat patients with a rare genetic condition called Fabry disease in an early clinical trial of a gene therapy it is developing, announcing Tuesday updated results from the first 11 study participants. Data […]


Cell and Gene Therapy, Industry

Beam details reasons for FDA hold on base editing cancer therapy

August 31, 2022

Via: Biopharma Dive

FDA officials are proceeding with caution as the gene editing field advances. In another recent example, the agency had issued a partial clinical hold to Editas Medicine before this July allowing that company to proceed with testing of a sickle […]


Cell and Gene Therapy, Industry, Manufacturing, Research and Development

Forecyte Bio and Cytiva to Collaborate on Cell and Gene Therapy Manufacturing and Development

August 31, 2022

Via: Biopharm International

Cytiva and Forecyte Bio announced on August 25, 2022 that they will collaborate to accelerate the manufacturing and development of the cell and gene therapy industry in China and the United States. The companies will utilize Cytiva’s Fast Trak center […]


Cell and Gene Therapy, Industry

Mayo Clinic, Hibiscus BioVentures and Innoforce Launch Mayflower Cell and Gene Therapy Accelerator

August 31, 2022

Via: Contract Pharma

Mayo Clinic, Hibiscus BioVentures and Innoforce Pharma have launched Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet patient needs. This academic and industry relationship will establish independent cell and […]


Cell and Gene Therapy, Industry

Applied StemCell Expands Cell and Gene Therapy Manufacturing Facility

August 31, 2022

Via: Contract Pharma

Applied StemCell, Inc. (ASC), a cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, is expanding its current good manufacturing (cGMP) facility. ASC has […]


Cell and Gene Therapy, Industry

Roctavian okay sets up another gene therapy test for Europe

August 26, 2022

Via: Pharmaphorum

The US biotech claimed conditional marketing approval from the European Commission for Roctavian (valoctocogene roxaparvovec) as a treatment for adults with severe haemophilia A, who don’t have a history of developing the antibodies that inhibit the activity of blood-clotting protein […]


Cell and Gene Therapy, Industry

With $2.8M gene therapy, Bluebird sets new bar for US drug pricing

August 18, 2022

Via: Biopharma Dive

Bluebird bio’s new gene therapy, approved in the U.S. Wednesday, offers patients with an inherited blood disorder a one-time, potentially curative, treatment option. But it will come at a price of $2.8 million, making the therapy the most expensive drug […]


Cell and Gene Therapy, Industry

Cellipont Unveils Plans for Cell Therapy Facility in Houston

August 18, 2022

Via: Contract Pharma

Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), has unveiled plans for a 76,000 square foot commercial-ready manufacturing facility for cell therapies and gene-modified cell therapies. Located in The Woodlands, TX, the facility will include state-of-the-art manufacturing, […]


Cell and Gene Therapy, Industry

‘Treg’ cell therapy: bringing CAR-T to autoimmune disease

August 16, 2022

Via: Biopharma Dive

Twelve years ago, Bill Ludwig and Doug Olson were running out of options when they enrolled in a clinical trial at the University of Pennsylvania. They had chronic lymphocytic leukemia, a type of blood cancer, and their disease had progressed […]


Cell and Gene Therapy, Industry

GentiBio partners with Bristol Myers as cell therapy for immune disease gains momentum

August 10, 2022

Via: Biopharma Dive

Biotechnology startup GentiBio on Wednesday struck a deal with Bristol Myers Squibb to develop a cell therapy for inflammatory bowel disease — the latest sign of the pharmaceutical industry’s interest in an emerging field of drug research. Through the alliance, […]


Cell and Gene Therapy, Industry, News

Sarepta says early filing for DMD gene therapy is back on

August 1, 2022

Via: Pharmaphorum

The US biotech – which already has three antisense drugs for DMD on the market – had said earlier it was planning to delay the application into 2023, so the new announcement marks an acceleration of its plans. Sarepta reported […]